+118.0%
NOK vs MRNA
+511.3%
-393.3%
-50.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.7% | -2.2% | +4.9% | +2.6% |
| 7D | -1.8% | +5.5% | -7.2% | -1.7% |
| 30D | +4.7% | +158.7% | -154.0% | +7.0% |
| 3M | -39.7% | +182.1% | -221.8% | -37.9% |
| 6M | +23.1% | +151.8% | -128.7% | +26.7% |
| YTD | +55.0% | +393.6% | -338.5% | +63.0% |
| 1Y | +118.0% | +499.5% | -381.4% | +125.3% |
| All | +118.0% | +511.3% | -393.3% | +125.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling